Form 4: Director Manuel Hidalgo Medina Exercises GH Stock Units

Director Manuel Hidalgo Medina acquired 232 shares of Guardant Health, Inc. common stock through the vesting of restricted stock units.

Summary

• Director Manuel Hidalgo Medina exercised 232 restricted stock units (RSUs) on April 17, 2026.
• The transaction resulted in the acquisition of 232 shares of common stock at a price of $0 per share.
• Following this transaction, the director holds a total of 1,657 shares of common stock directly.
• The RSUs were part of an award granted on July 17, 2024, which follows a four-year vesting schedule.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event related to standard director compensation.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified in this filing.

Risks

• None identified in this filing.

Future Outlook

The remaining 75% of the July 17, 2024, RSU award continues to vest on a monthly basis over the three-year period following the initial July 2025 vesting date.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is a standard component of executive and board compensation packages in the biotechnology sector, signaling no change in strategic direction or insider sentiment.

Comparison to Industry Standards

• The transaction follows standard equity compensation practices common among mid-cap biotech firms.
• The vesting schedule is consistent with typical long-term incentive plans for board members at companies like Exact Sciences or Natera.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Continued monthly vesting of the remaining 75% of the July 2024 RSU award.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Trading, Equity Compensation, Manuel Hidalgo Medina